Warning: The NCBI web site requires JavaScript to function. more...
The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial.
Findling RL, Pagano ME, McNamara NK, Stansbrey RJ, Faber JE, Lingler J, Demeter CA, Bedoya D, Reed MD.
Child Adolesc Psychiatry Ment Health. 2009 Mar 19;3(1):11.
Related citations
Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.
J Clin Psychiatry. 2004 Oct;65(10):1356-64.
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
Clin Ther. 2009 Jun;31 Pt 1:1405-23.
A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes.
Barbosa L, Berk M, Vorster M.
J Clin Psychiatry. 2003 Apr;64(4):403-7.
Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.
Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG.
J Am Acad Child Adolesc Psychiatry. 2002 Oct;41(10):1205-15.
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J; Treatment for Adolescents With Depression Study (TADS) Team.
JAMA. 2004 Aug 18;292(7):807-20.
Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
Clin Ther. 2006 Feb;28(2):266-79.
A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.
DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM.
Bipolar Disord. 2009 Aug;11(5):483-93.
[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.
Encephale. 2009 Dec;35(6):595-604. Epub . French.
Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.
Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, Wood DS, Brown SJ.
Drug Alcohol Depend. 2010 Nov 1;112(1-2):39-45. Epub 2010 Jun 23.
A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.
Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J.
Arch Gen Psychiatry. 1997 Nov;54(11):1031-7.
The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J.
Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101.
Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R.
Clin Ther. 2006 Mar;28(3):402-18.
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.
Arthritis Rheum. 2004 Sep;50(9):2974-84.
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M.
J Clin Psychiatry. 2009 Oct;70(10):1424-31.
Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.
Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D; Sertraline Pediatric Depression Study Group.
JAMA. 2003 Aug 27;290(8):1033-41.
Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial.
Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, Kuijpers PM, Wellens HJ, Van Praag HM.
Psychosom Med. 2000 Nov-Dec;62(6):783-9.
Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group.
Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I.
J Clin Psychiatry. 1998 May;59(5):217-24.
A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders.
Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK.
Arch Pediatr Adolesc Med. 2007 Nov;161(11):1026-34.
[Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L, Corcos M, Jeammet P.
Encephale. 2005 May-Jun;31(3):309-16. French.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on